title: Local application of L- threo-hydroxyaspartate and malonate in rats in vivo induces rigidity and damages neurons of the substantia nigra, pars compacta.
abstract: In order to study neuronal death in Parkinson's disease, neurons of the substantia nigra, pars compacta in rats were exposed to elevated levels of glutamate and decreased levels of energy in vivo and consequences for behavior and neuronal morphology were studied. Thus, repeated local injections (9x) of the glutamate uptake inhibitor L- threo-hydroxyaspartate (L-THA; 833 microM in 0.3 microl) in the presence or absence of the succinate dehydrogenase inhibitor malonate (25 mM in 0.3 microl) were applied during three weeks. 24 h after injection, rigidity and catalepsy were measured, as well as, at the end of the three week period, locomotion, rearing and exploratory behavior. Thereafter, the cytoarchitecture of the substantia nigra, pars compacta of the brains of these rats was described. The L-THA plus malonate injected rats did not differ in their behavior from carrier injected rats, except for rigidity: their scores were higher than that of carrier and L-THA injected rats (P < 0.05), while L-THA injected rats did not differ from carrier injected controls. Observations on cresyl violet sections revealed, that, although many neurons with a shrunken nucleolus and faintly stained cytoplasm were present in both L-THA and L-THA plus malonate treated rats, the ventral edge of the substantia nigra, pars compacta containing modified cells was longer in L-THA plus malonate than in L-THA injected rats (P < 0.05). This indicates, that a minimum amount of damage to neurons in the ventral part of the substantia nigra, pars compacta might be required for the expression of rigidity.
authors.affiliation: Zoologisches Institut, Neuropharmakologie, Universität Tübingen, Medizinisches Wissenschaftliches Forschungszentrum, Tübingen, Federal Republic of Germany. l.d.loopuyt@uni-tuebingen.de
authors.forename: L D
authors.initials: LD
authors.lastname: Loopuijt
mesh_terms: D000818:Animals; D001224:Aspartic Acid / Q000031:analogs & derivatives / Q000633:toxicity*; D001522:Behavior, Animal / Q000187:drug effects; D001931:Brain Mapping; D002375:Catalepsy / Q000139:chemically induced / Q000473:pathology; D002452:Cell Count; D004396:Coloring Agents; D008124:Locomotion / Q000187:drug effects; D008297:Male; D008314:Malonates / Q000633:toxicity*; D009127:Muscle Rigidity / Q000139:chemically induced* / Q000473:pathology; D009410:Nerve Degeneration / Q000139:chemically induced / Q000473:pathology; D009474:Neurons / Q000187:drug effects* / Q000473:pathology; D010302:Parkinson Disease, Secondary / Q000473:pathology; D051381:Rats; D017207:Rats, Sprague-Dawley; D013378:Substantia Nigra / Q000187:drug effects* / Q000473:pathology*
chemical_list: D004396:Coloring Agents; D008314:Malonates; C011274:3-hydroxyaspartic acid; D001224:Aspartic Acid; C030290:malonic acid